Press release: EORTC partners with IBBL to support precision medicine clinical research

Brussels, Sept 27, 2016 EORTC and IBBL (Integrated BioBank of Luxembourg) announce their partnership to support precision medicine clinical research. This far-reaching collaboration includes handling and storing of human biological material from EORTC studies at IBBL, initiatives in biospecimen research in the context of the EORTC SPECTA program, training programs for pathologists involved in tissue handling for clinical trials in personalized cancer treatment, and infrastructures to support discovery and validation of diagnostic, prognostic, or predictive biomarkers in cancer.

This partnership will ensure that the significant strengths of both organizations will combine to allow expansion of their respective portfolios.

“We strive to form a network of professional not-for-profit institutions that is much more than the sum of its parts. Our vision is to always produce highest-quality research, aiming for robustness, reproducibility, and reduction of bias,” said Vassilis Golfinopoulos, Medical Director at EORTC. “By working with IBBL and building on the SPECTA infrastructure, we offer to European researchers a research platform with a level of quality and cost-effectiveness only available to a few select institutions so far. This system will open more opportunities for clinicians to develop innovative trials and valuable translational research.”

EORTC’s SPECTA (Screening Patients for Efficient Clinical Trial Access) initiative is a pan-European biobank and molecular profiling platform for patients in colorectal, brain, lung, melanoma, and rare cancers, which aims to optimize drug access, help advance the development of targeted treatments and accelerate new healthcare delivery. Built as a collaborative network, SPECTA provides access to large sets of patient-level clinical and biological data for international, multidisciplinary clinical research.

“We are proud to become EORTC’s partner of choice for the management and storage of biosamples in the context of their clinical research,” said Marc Vandelaer, CEO of IBBL. “This partnership supports our mission of providing accredited bioservices and a biobanking infrastructure for applied medical research.”


The European Organisation for the Research and Treatment of Cancer (EORTC) brings together European cancer clinical research experts from all disciplines for trans-national collaboration. Both multinational and multidisciplinary, the EORTC network comprises more than 4,600 collaborators from all disciplines involved in cancer treatment and research in more than 640 hospitals in over 37 countries. A unique pan-European non-profit clinical research infrastructure, EORTC offers an integrated approach to drug development, drug evaluation programs and medical practices through translational and clinical research.

About IBBL

IBBL (Integrated BioBank of Luxembourg) is an autonomous not-for-profit institute dedicated to supporting biomedical research for the benefit of patients. IBBL is an integrated research infrastructure offering bioservices, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is ISO 9001:2008 and NF S96-900:2011 certified, as well as ISO 17025:2005 accredited*. IBBL’s mission is to provide biospecimen related services and a biobanking infrastructure for applied medical research. IBBL’s vision is to be an international centre of excellence in biobanking and a valued partner in developing better healthcare solutions. IBBL is an autonomous institute, organised within the Luxembourg Institute of Health (LIH). For more information, please visit ( or (

Back to news list